For the second time in the space of a month AstraZeneca has stopped a trial of its chronic lymphocytic leukaemia (CLL) drug Calquence (acalabrutinib) early following positive results.
AstraZeneca has said that it will stop a Phase III trial of its chronic lymphocytic leukaemia drug Calquence (acalabrutinib) early after the drug met its primary endpoint in an interim anal
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS